Electroacupuncture Alleviates Neuropathic Pain by Inhibiting Spinal CCL2-Driven Microglial Activation.

Researchers have discovered how electroacupuncture may relieve nerve pain by targeting specific immune processes in the spinal cord. Scientists studied rats with nerve injury-induced pain, applying electroacupuncture to two commonly used acupuncture points on the leg (ST36 and GB34) for 30 minutes daily over five days. The treatment used mild electrical stimulation at 1 milliamp and 2 Hz frequency.

The study found that electroacupuncture significantly reduced both pain sensitivity to touch and heat in treated animals. When researchers examined spinal cord tissue, they discovered that electroacupuncture decreased levels of CCL2, a signaling protein that activates immune cells called microglia. These activated microglia contribute to chronic pain by releasing inflammatory chemicals. The electroacupuncture treatment lowered both microglial activation and inflammatory markers in the spinal cord.

To confirm their findings, researchers administered synthetic CCL2 directly into the spinal fluid of treated animals. This completely reversed the pain-relieving effects of electroacupuncture, proving that blocking CCL2 signaling is essential to how electroacupuncture works for nerve pain.

These findings help explain the biological mechanisms behind electroacupuncture's effectiveness for neuropathic pain conditions like sciatica, diabetic neuropathy, or post-surgical nerve pain. The research suggests that electroacupuncture doesn't simply mask pain but actively reduces inflammation in the nervous system. While this study used animal models, it provides scientific support for electroacupuncture as a treatment option for chronic nerve pain in humans. If you're considering electroacupuncture for nerve pain, consult with a licensed acupuncturist trained in electroacupuncture techniques.

This rat model study (L5 spinal nerve ligation) investigated electroacupuncture's mechanisms in neuropathic pain management. EA was delivered at ST36 and GB34 (1 mA, 2 Hz, 30 minutes daily, POD 3-7) using anesthetized control, non-acupoint, and acupoint groups. Results demonstrated significant attenuation of mechanical allodynia and thermal hyperalgesia in the acupoint group. Western blot and immunofluorescence analyses revealed reduced expression of CCL2, CCR2, microglial marker Iba1, IL-1β, and TNF-α in L4-L6 spinal cord segments. Critically, intrathecal administration of recombinant CCL2 completely abolished EA's analgesic effects, establishing causal necessity of CCL2/CCR2 pathway inhibition. Clinical implications suggest EA's analgesic mechanism operates through downregulation of spinal chemokine signaling and microglial activation rather than peripheral mechanisms alone. This supports EA protocols targeting distal lower extremity points for neuropathic pain conditions, with treatment frequency of 5 consecutive days showing measurable anti-inflammatory effects at the spinal level.